Loading news...
Enhabit, Inc. (NYSE: EHAB - Get Free Report) has received an average rating of "Moderate Buy" from the eight research firms that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Enhabit (EHAB) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Small-cap stocks are leading the way to start 2026, outgunning larger rivals after lagging for a decade. Conditions are favorable for small-cap stocks to maintain solid momentum in 2026 as they stand to gain from easing rates, broadening earnings growth, and cooling trade tensions. Small-cap stocks have outperformed in the past 12 months and are trading at discounted valuations relative to mid-sized and large-cap peers.
Medical services stocks like MEDP, EHAB and PGNY benefit from tech-driven care models even as staffing gaps pressure margins.
Enhabit (NYSE: EHAB - Get Free Report) and Ryman Healthcare (OTCMKTS:RYHTY - Get Free Report) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations. Profitability This table compares Enhabit and Ryman Healthcare's net
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Enhabit (EHAB) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Here is how Enhabit (EHAB) and Gain Therapeutics, Inc. (GANX) have performed compared to their sector so far this year.
Enhabit, Inc. (EHAB) Presents at Bank of America Home Care Conference Transcript
DALLAS--(BUSINESS WIRE)--Enhabit, Inc. (NYSE: EHAB), a leading national home health and hospice provider, today announced its participation in the Bank of America Home Care Conference 2025. Enhabit's President and CEO Barb Jacobsmeyer and Chief Financial Officer Ryan Solomon will participate in a fireside chat on Tuesday, Dec. 9, at 2:50 p.m. CT. The fireside chat will be webcast live at https://bofa.veracast.com/webcasts/bofa/homecare2025/M4EufU.cfm, and a replay will be available at the same.
Here is how Enhabit (EHAB) and Ensign Group (ENSG) have performed compared to their sector so far this year.
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Enhabit (EHAB) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Enhabit, Inc. ( EHAB ) UBS Global Healthcare Conference 2025 November 11, 2025 12:30 PM EST Company Participants Barbara Jacobsmeyer - President, CEO & Director Ryan Solomon - Chief Financial Officer Presentation Operator All right. I think we're getting to get started here.
Enhabit (EHAB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Enhabit, Inc. ( EHAB ) Q3 2025 Earnings Call November 6, 2025 9:00 AM EST Company Participants Bob Okunski Barbara Jacobsmeyer - President, CEO & Director Ryan Solomon - Chief Financial Officer Conference Call Participants Meghan Holtz - Jefferies LLC, Research Division Christian Borgmeyer - TD Cowen, Research Division Presentation Operator Thank you for standing by. My name is Kathleen, and I will be your conference operator today.
Enhabit (EHAB) came out with quarterly earnings of $0.17 per share, beating the Zacks Consensus Estimate of $0.12 per share. This compares to earnings of $0.03 per share a year ago.
DALLAS--(BUSINESS WIRE)--Enhabit, Inc. (NYSE: EHAB), a leading home health and hospice care provider, today reported its results of operations for the third quarter ended Sept. 30, 2025. “Our third quarter results reflect strong execution on our core strategic priorities, with year-over-year growth in revenue, census and Adjusted EBITDA,” said Barb Jacobsmeyer, president and CEO of Enhabit. “This progress allowed us to further reduce our bank debt and strengthen the balance sheet during the qua.
Enhabit (NYSE: EHAB - Get Free Report) and Pediatrix Medical Group (NYSE: MD - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, analyst recommendations, dividends and risk. Analyst Ratings This is a breakdown of
DALLAS--(BUSINESS WIRE)--Enhabit, Inc. (NYSE: EHAB), a leading national home health and hospice provider, today announced its participation in the UBS Global Healthcare Conference 2025. Enhabit's President and CEO Barb Jacobsmeyer and Chief Financial Officer Ryan Solomon will participate in a fireside chat on Tuesday, Nov. 11 at 11:30 a.m. CT. The fireside chat will be webcast live and available for replay on Enhabit's investor website. About Enhabit Home Health & Hospice Enhabit Home Healt.
DekaBank Deutsche Girozentrale grew its stake in Enhabit, Inc. (NYSE: EHAB) by 24.4% during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 423,412 shares of the company's stock after purchasing an additional 83,000 shares during the quarter. DekaBank Deutsche Girozentrale owned
DALLAS--(BUSINESS WIRE)--Enhabit, Inc. (NYSE: EHAB), a leading national home health and hospice provider, today announced it will report its financial results for the third quarter ended Sept. 30, 2025, on Nov. 5, 2025, and host a webcast and conference call on Nov. 6, 2025. Individuals who would like to participate in the conference call webcast should join 15 minutes before the scheduled start time. Nov. 6, 2025 9 a.m. EST Toll-free: 888-660-6150 International: 929-203-0843 Conference ID: 524.